Trillium Therapeutics Inc (TRIL)

[biocqr]

FTSV > target raised to $60 by Oppy...

Forty Seven price target raised to $60 from $35 at Oppenheimer Oppenheimer analyst Mark Breidenbach raised his price target for Forty Seven to $60 from $35 and reiterated an Outperform rating after meeting with management to review recent progress and objectives for 2020.

The analyst tells investors in a research note that near term, Forty Seven plans to initiate two pivotal trials evaluating magrolimab in myelodysplastic syndrome and diffuse large B-cell lymphoma, and says thanks to a recent $195.6M capital raise, the company is funded into 1Q22, potentially beyond critical catalysts including top-line pivotal data in MDS.

Read more at:
https://thefly.com/landingPageNews.php?id=3019654